Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iruplinalkib
- Development stage
- Phase 3
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Iruplinalkib is an orally available, small molecule inhibitor of the anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases. It is developed by Qilu Pharmaceuticals for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with ALK-positive NSCLC. Iruplinalkib has shown efficacy against both wild-type ALK and ALK resistance mutations, such as L1196M and G1202R. It was approved in China for the treatment of ALK-positive, crizotinib-resistant or crizotinib-intolerable NSCLC.
- Brand names
- Qixinke
- Other names
- Z5F65W1YAZZ-5F65W1YAZZ 5F65W1YAZ
02
Targets
ABCG2 (Breast cancer resistance protein)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)EGFR (Epidermal growth factor receptor)SLC47A1 (Multidrug and toxin extrusion transporter 1)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ABCB1 (P-glycoprotein)MATE2-K (Multidrug and toxin extrusion protein 2)
Beyond the preview
Go deeper on iruplinalkib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iruplinalkib.